The European Union may approve the sale of Remdesivivirier to treat Coronavirus

The European Union can provide an initial green light in the coming days for sale of Remdesivitri as a treatment for COVID-19, the head of its drug agency said on Monday, quickly following the market medicine in the midst of close global competition, reports Knon, broadcast news.net.

The United States, which has angered the EU with aggressive tactics in a procurement race during the global pandemic, has still not issued a similar approval for the medicine, made by the American pharmaceutical company Gilead.

The demand for Remdesivir is on the rise, since there are currently no treatments or vaccines approved for COVID-19, respiratory disease caused by the new coronary.

The “could be that a parole market authorisation could be issued in the coming days,” said the head of the European Union's drug agency, Guydo Rasi, at a hearing at the EU Parliament in Brussels on Monday, broadcasts news.

An EU conditional marketing authorisation allows a drug to be sold for a year in the 27-nation bloc before all necessary data is available for its efficiency and side effects, Reuters reports.

The European Bars Agency (EMA) has already recommended the use of Remdesivir, which allows a drug to be administered to patients even before its sale is authorised.